About Haemonetics

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. 

Our legacy of innovation was built on a dynamic approach to product development and customer support, an entrepreneurial-minded culture, and an unwavering commitment to quality, integrity and "making it matter" to patients around the world.

About Haemonetics
Corporate Governance

CORPORATE RESPONSIBILITY

Leading with our Values

We are committed to operating responsibly, conserving resources and meeting all environmental requirements that apply to us. As a Company, we are also committed to making our workplaces safe and secure.

Committed to Integrity

CORPORATE GOVERNANCE

Committed to Integrity

We measure our success not only by our achievements but by our adherence to the highest standards of accountability in everything we do.

Team At Table

HAEMONETICS LEADERSHIP

Purpose, passion, performance

Our leadership team sets the example for how we make it matter every day by living our Values: Think Big, Take Action, Win Together, and Always Learn and Improve.

Our History

1968

The Latham Bowl Is Invented

1971

Haemonetics Is founded

1974

Cell Saver® System Is Introduced

1981

Haemonetics Opens Its First International Headquarters

1984

PCS® Plasma Collection System Launches

1991

A public company

The company is taken public again, successfully completing an initial public offering (HAE) on the New York Stock Exchange.

1992

MCS® Mobile Apheresis System Launches, Making Blood Component Therapy Possible At Blood Banks

1993

PCS® 2 Launches, Introducing Blow-Molded Plasma Collection Bowl

1995

MCS®+ Mobile Platelet Collection System Launches

2003

ACP® 215 System Cell Washing Protocol Is Introduced

2008

Haemonetics Acquires TEG® 5000 Hemostasis Analyzer

2009

Haemonetics Invests in Information Management & Technology

2010

BloodTrack® & SafeTrace Tx® Systems Added to the Hospital Portfolio

2011

Cell Saver® Elite® System Launches

2015

BloodTrack® HaemoBank® Blood Management System Is Introduced

2015

TEG® 6s Analyzer And TEG Manager® Software Are Introduced

2017

Cell Saver® Elite®+ System Launches

2017

NexSys PCS® Plasma Collection System Launches

2018

NexLynk DMS® Software Launches

2018

YES® Technology For NexSys PCS® Receives FDA 510(k) Clearance

2019

Haemonetics Releases New SafeTrace Tx® Transfusion Management Software

2019

Haemonetics Opens New HQ in Boston

2020

The NexSys PCS® System With Persona® Technology Launches

2021

Haemonetics Acquires the VASCADE® Product Family

2022

Haemonetics Opens New Center of Excellence in Clinton, PA

2022

Haemonetics Earns MDR CE Mark for VASCADE® Portfolio

2023

Haemonetics Earns Approval in Japan for VASCADE MVP®

2023

Haemonetics Launches Cell Saver® Elite® + with Intelligent Control

2023

Haemonetics Earns FDA Clearance for New Plasma Collection Bowl and Express® Plus Software for the NexSys PCS® Plasma Collection Device

2023

Haemonetics Acquires OpSens Inc. and the SavvyWire® Pre-Shaped Pressure Guidewire and the OptoWire® Pressure Guidewire Technologies

2024

Haemonetics Acquires Attune Medical and the ensoETM® Proactive Esophageal Cooling Device

2024

Haemonetics launches TEG® 6s Global Hemostasis - HN cartridge in the U.S.

2024

Haemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure Guidewire

2024

Haemonetics Launches the VASCADE MVP® XL Mid-Bore Venous Closure System